Cytokines in cancer pathogenesis and cancer therapy, Nat Rev Cancer, vol.4, pp.11-22, 2004. ,
Identification of a putative second T-cell receptor, Nature, vol.322, pp.145-154, 1986. ,
Complete primary structure of a heterodimeric T-cell receptor deduced from cDNA sequences, Nature, vol.309, pp.757-62, 1984. ,
Evolution of the VD and J gene segments used in the primate ? ? T-cell receptor reveals a dichotomy of conservation and diversity, Proc Natl Acad Sci, vol.108, pp.332-372, 2011. ,
Tcell receptor gamma/delta: comparison of gene configurations and function between humans and chimpanzees, Immunogenetics, vol.36, pp.294-301, 1992. ,
Gamma-delta (??) T cells: friend or foe in cancer development?, J Transl Med, vol.16, p.3, 2018. ,
Evolution and function of the TCR Vgamma9 chain repertoire: it's good to be public, Cell Immunol, vol.141, pp.22-30, 1990. ,
Six-of-the-best: unique contributions of ?? T cells to immunology, Nat Rev Immunol, vol.13, pp.88-100, 2013. ,
Butyrophilin 2A1 is essential for phosphoantigen reactivity by ?? T cells, Science, vol.367, p.5516, 2020. ,
Butyrophilin-2A1 directly binds germline-encoded regions of the V?9V?2 TCR and is essential for phosphoantigen sensing, Immunity, vol.52, pp.487-98, 2020. ,
Towards deciphering the hidden mechanisms that contribute to the antigenic activation process of human V?9V?2 T cells, Front Immunol, vol.9, p.828, 2018. ,
Targeting lipid biosynthesis and salvage in apicomplexan parasites for improved chemotherapies, Nat Rev Microbiol, vol.11, pp.823-858, 2013. ,
Statins prevent bisphosphonate-induced ? ,?-T-cell proliferation and activation in vitro, J Bone Miner Res Off J Am Soc Bone Miner Res, vol.19, pp.278-88, 2004. ,
Five layers of receptor signaling in ?? T-cell differentiation and activation, Front Immunol, vol.6, p.15, 2015. ,
Improving the efficiency of V?9V?2 T-cell immunotherapy in cancer, Front Immunol, vol.9, p.800, 2018. ,
Human T cell receptor ? ? cells recognize endogenous mevalonate metabolites in tumor cells, J Exp Med, vol.197, pp.163-171, 2003. ,
Molecules and mechanisms implicated in the peculiar antigenic activation process of human V?9V?2 T cells, Front Immunol, vol.5, p.657, 2014. ,
?? T cells in cancer, Nat Rev Immunol, vol.15, pp.683-91, 2015. ,
Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma, Blood, vol.96, pp.384-92, 2000. ,
Human V? 9-V?2 T cell receptor-gamma delta lymphocytes show specificity to Daudi Burkitt's lymphoma cells, J Immunol Baltim Md, vol.145, pp.3202-3210, 1990. ,
Gamma/delta T cells provide innate immunity against renal cell carcinoma, Cancer Immunol Immunother CII, vol.50, pp.115-139, 2001. ,
Phosphostim-activated ? ? T cells kill autologous metastatic renal cell carcinoma, J Immunol Baltim Md, vol.174, pp.1338-1385, 1950. ,
V? 9V?2 T cell response to colon carcinoma cells, J Immunol Baltim Md, vol.175, pp.5481-5489, 1950. ,
Preferential Th1 cytokine profile of phosphoantigen-stimulated human V?9V?2 T cells, Mediators Inflamm, p.704941, 2010. ,
Single-cell cytokine analysis of gamma delta T cell responses to nonpeptide mycobacterial antigens, J Immunol Baltim Md, vol.159, pp.1328-1363, 1950. ,
The distinct contributions of murine T cell receptor (TCR)??+ and TCR??+ T cells to different stages of chemically induced skin cancer, J Exp Med, vol.198, pp.747-55, 2003. ,
Characterization of tumor reactivity of human V? 9V?2? ? T cells in vitro and in SCID mice in vivo, J Immunol Baltim Md, vol.173, pp.6767-76, 1950. ,
Anti-tumor effects of human peripheral ? ? T cells in a mouse tumor model, Int J Cancer, vol.92, pp.421-426, 2001. ,
The prognostic landscape of genes and infiltrating immune cells across human cancers, Nat Med, vol.21, pp.938-983, 2015. ,
Tumor-infiltrating ?? T lymphocytes: pathogenic role, clinical significance, and differential programing in the tumor microenvironment, Front Immunol, vol.5, p.607, 2014. ,
What lessons can be learned from ?? T cell-based cancer immunotherapy trials?, Cell Mol Immunol, vol.10, pp.35-41, 2013. ,
Translating gammadelta (??) T cells and their receptors into cancer cell therapies, Nat Rev Drug Discov, vol.19, pp.169-84, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02407109
? /? T-cell stimulation by pamidronate, N Engl J Med, vol.340, pp.737-745, 1999. ,
? ? T cells for immune therapy of patients with lymphoid malignancies, Blood, vol.102, pp.200-206, 2003. ,
Induction of ? ? T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo, Blood, vol.102, pp.2310-2311, 2003. ,
Targeting human ? ? T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer, Cancer Res, vol.67, pp.7450-7457, 2007. ,
Pilot trial of interleukin-2 and zoledronic acid to augment ?? T cells as treatment for patients with refractory renal cell carcinoma, Cancer Immunol Immunother CII, vol.60, pp.1447-60, 2011. ,
In vivo manipulation of V? 9V?2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients, Clin Exp Immunol, vol.161, pp.290-297, 2010. ,
Successful adoptive transfer and in vivo expansion of haploidentical ?? T cells, J Transl Med, vol.12, p.45, 2014. ,
Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a V? 9V?2 T lymphocyte agonist in patients with solid tumors, Cancer Immunol Immunother CII, vol.59, pp.1521-1551, 2010. ,
In vivo immunomanipulation of V? 9V?2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model, J Immunol Baltim Md, vol.175, pp.5471-80, 1950. ,
Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study, Cancer Immunol Immunother CII, vol.56, pp.469-76, 2007. ,
Allogenic V?9V?2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma, J Immunother Cancer, vol.7, p.36, 2019. ,
?? T cells for cancer immunotherapy: a systematic review of clinical trials, Oncoimmunology, vol.3, p.27572, 2014. ,
GMP-grade manufacturing of T cells engineered to express a defined ??TCR, Front Immunol, vol.9, p.1062, 2018. ,
Repeated systemic administrations of both aminobisphosphonates and human V?9V?2 T cells efficiently control tumor development in vivo, J Immunol Baltim Md, vol.191, 1950. ,
Preclinical research: make mouse studies work, Nature, vol.507, pp.423-428, 2014. ,
Humanized mouse models for the preclinical assessment of cancer immunotherapy, BioDrugs Clin Immunother Biopharm Gene Ther, vol.32, pp.245-66, 2018. ,
Stereotaxic administrations of allogeneic human V?9V?2 T cells efficiently control the development of human glioblastoma brain tumors, Oncoimmunology, vol.5, p.1168554, 2016. ,
IL-21 increases the reactivity of allogeneic human V?9V?2 T cells against primary glioblastoma tumors, J Immunother Hagerstown Md 1997, vol.41, pp.224-255, 2018. ,
Combined chemotherapy and allogeneic human V?9V?2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo, Oncoimmunology, vol.8, p.1649971, 2019. ,
The generation and application of patient-derived xenograft model for cancer research, Cancer Res Treat Off J Korean Cancer Assoc, vol.50, pp.1-10, 2018. ,
Humanized mouse xenograft models: narrowing the tumor-microenvironment gap, Cancer Res, vol.76, pp.6153-6161, 2016. ,
Gamma delta T cell therapy for cancer: it is good to be local, Front Immunol, vol.9, p.1305, 2018. ,
Intravesical administration of ? ? T cells successfully prevents the growth of bladder cancer in the murine model, Cancer Immunol Immunother CII, vol.58, pp.493-502, 2009. ,
NKG2D controls natural reactivity of V?9V?2 T lymphocytes against mesenchymal glioblastoma cells, Clin Cancer Res Off J Am Assoc Cancer Res, vol.25, pp.7218-7246, 2019. ,
NKG2D-and T-cell receptor-dependent lysis of malignant glioma cell lines by human ?? T cells: modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors, Oncoimmunology, vol.5, p.1093276, 2016. ,
Chemotherapy sensitizes colon cancer initiating cells to V?9V?2 T cell-mediated cytotoxicity, PLoS ONE, vol.8, p.65145, 2013. ,
Ex vivo expanded patient-derived ?? T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model, Oncoimmunology, vol.8, p.1593804, 2019. ,
Boosting ?? T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma, Oncoimmunology, vol.8, p.1554175, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02347205
Stimulated ?? T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer ,
, , vol.187, pp.1031-1039, 1950.
Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies, Blood, vol.113, pp.4875-84, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-02348974
A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of V?9V?2-T cells, Oncoimmunology, vol.7, p.1375641, 2017. ,
BTN3A molecules considerably improve V?9V?2T cellsbased immunotherapy in acute myeloid leukemia, Oncoimmunology, vol.5, p.1146843, 2016. ,
IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V? 9V?2 T cells for adoptive immunotherapy, J Immunol Baltim Md, vol.182, pp.3423-3454, 1950. ,
Vitamin C promotes the proliferation and effector functions of human ?? T cells, Cell Mol Immunol, vol.17, pp.462-73, 2019. ,